Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Leukemia. 2014 Oct 6;29(4):807–818. doi: 10.1038/leu.2014.296

Figure 4. Exposure to AZD1775 results in Chk1 activation and cdc2/Cdk1 T14 phosphorylation, events blocked by HDACIs.

Figure 4

(a–c) U937 (a), MV-4-11 (b), and MOLM-13 (c) cells were treated (24 h) with the indicated concentrations of AZD1775 +/− Vorinostat or SBHA, after which Western blot analysis was performed to examine phosphorylation (S296, S317, S345) and protein levels of Chk1. (d–f) Alternatively, the mitotic entry marker histone H3 S10 phosphorylation, T14 phosphorylation of cdc2/Cdk1, and total protein levels were monitored in parallel.